NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis $3.76 +0.02 (+0.53%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About C4 Therapeutics Stock (NASDAQ:CCCC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get C4 Therapeutics alerts:Sign Up Key Stats Today's Range$3.66▼$3.8550-Day Range$3.40▼$4.6752-Week Range$1.69▼$5.17Volume2.36 million shsAverage Volume2.68 million shsMarket Capitalization$462.59 millionP/E RatioN/ADividend YieldN/APrice Target$7.67Consensus RatingModerate Buy Company Overview C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies. The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages. Lead programs are directed at hematologic malignancies, solid tumors and other serious diseases. C4 Therapeutics has established strategic collaborations with major pharmaceutical partners to leverage its CiD platform across various therapeutic areas. These partnerships provide access to joint research and development resources, accelerating the advancement of novel degrader molecules into human studies. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics operates research laboratories in the United States and collaborates with academic institutions and contract research organizations worldwide. The company employs a multidisciplinary team of chemists, biologists and drug development experts to drive its discovery engine and translate early-stage assets into clinical candidates. C4 Therapeutics is led by a management team with extensive experience in protein chemistry, drug discovery and clinical development. The company’s leadership includes seasoned biotechnology executives and scientific advisors who guide its efforts to bring next-generation protein degraders to patients. Through its innovative platform, C4 Therapeutics aims to expand the therapeutic possibilities for diseases driven by previously “undruggable” targets.AI Generated. May Contain Errors. Read More C4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreCCCC MarketRank™: C4 Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 763rd out of 912 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingC4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialC4 Therapeutics has a consensus price target of $7.67, representing about 103.6% upside from its current price of $3.77.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($0.85) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -3.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.32% of the float of C4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 13.93, which indicates bearish sentiment.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 11.90%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment0.56 News SentimentC4 Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for C4 Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.60% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CCCC Stock News HeadlinesC4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple ...September 3 at 3:27 PM | markets.businessinsider.comC4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual MeetingSeptember 3 at 7:00 AM | globenewswire.comThe ultimate IPO unicorn before Labor DayAnthropic is now valued at over $1 trillion, more than every U.S. airline combined and larger than the U.S. defense budget. Its annualized revenue grew 80x in the first quarter, and an IPO could arrive as early as October. For a limited time, investors can access a report detailing how to explore a pre-IPO stake in Anthropic for $29, a 94% discount off the retail price. The package includes a year of Disruptors and Dominators, monthly stock ideas, and four special reports.September 4 at 1:00 AM | Weiss Ratings (Ad)C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 25, 2026 | americanbankingnews.comC4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 11, 2026 | finance.yahoo.comC4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?July 3, 2026 | insidermonkey.comC4 Therapeutics Shareholders Back Directors, Pay and AuditorsJune 24, 2026 | tipranks.comC4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - SlideshowJune 20, 2026 | seekingalpha.comSee More Headlines CCCC Stock Analysis - Frequently Asked Questions How have CCCC shares performed this year? C4 Therapeutics' stock was trading at $1.91 at the beginning of 2026. Since then, CCCC stock has increased by 97.1% and is now trading at $3.7650. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.05. The firm earned $6.64 million during the quarter, compared to analyst estimates of $4 million. C4 Therapeutics had a negative net margin of 289.44% and a negative trailing twelve-month return on equity of 45.45%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $163 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 9,600,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank acted as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? Top institutional shareholders of C4 Therapeutics include Wasatch Advisors LP (3.19%), Velan Capital Investment Management LP (0.46%), Seven Fleet Capital Management LP (0.31%) and Bank of New York Mellon Corp (0.23%). Insiders that own company stock include Leonard Reyno and Scott N Boyle. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of C4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that C4 Therapeutics investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD), NVIDIA (NVDA) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/11/2026Today9/04/2026Wells Fargo 21st Annual Healthcare Conference9/10/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CCCC's financial health is in the Green zone, according to TradeSmith. CCCC has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CCCC CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees150Year Founded2015Price Target and Rating Average Price Target for C4 Therapeutics$7.67 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+103.9%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$104.99 million Net Margins-289.44% Pretax Margin-289.09% Return on Equity-45.45% Return on Assets-30.90% Debt Debt-to-Equity RatioN/A Current Ratio5.45 Quick Ratio5.45 Sales & Book Value Annual Sales$35.95 million Price / Sales12.87 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book1.87Miscellaneous Outstanding Shares123,030,000Free Float116,136,000Market Cap$462.59 million OptionableOptionable Beta2.94 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CCCC) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersCongress Just Opened the FloodgatesThe House passed the Digital Asset Market Clarity Act 294 to 134, creating the most comprehensive financial te...Awesomely | SponsoredAnthropic’s $65 Billion Surge: One backdoor got there firstAnthropic's annualized revenue run rate hit $65 billion, up from $47 billion in May and roughly $9 billion at ...The Oxford Club | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more e...Eagle Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredNear retirement? Buy this stockOn August 9, the Wall Street Journal profiled a unique AI strategy used by three companies. Whitney Tilson of ...Stansberry Research | SponsoredTrump’s “new Petrodollar” exposedTrump has reportedly secured control over 65 billion barrels across 17 Venezuelan oil fields, more than the en...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
